GSK plans to rebuild battered company

GlaxoSmithKline, battered by weak US drug sales and a bribery scandal inChina, set out a bold recovery plan yesterday, including an initial public offering of part of its fast-growing HIV and AIDS drugs business.

GSK plans to rebuild battered company

As a standalone company ViiV Healthcare would be among the top 40 companies in London’s FTSE 100 index, outranking Marks and Spencer, GSK chief executive Andrew Witty told reporters. Analysts at Jefferies said they valued the HIV and AIDS division at about £17bn (€21.6bn).

Announcing third-quarter results, Britain’s biggest drugmaker also set out the latest in a string of cost-cutting programmes and said that its 2015 dividend is expected to be kept at the same level as this year’s 80p a share.

Already a subscriber? Sign in

You have reached your article limit.

Unlimited access. Half the price.

Annual €130 €65

Best value

Monthly €12€6 / month

More in this section

The Business Hub

Newsletter

News and analysis on business, money and jobs from Munster and beyond by our expert team of business writers.

Cookie Policy Privacy Policy Brand Safety FAQ Help Contact Us Terms and Conditions

© Examiner Echo Group Limited